ArticleThe Lancet. Rheumatology2020

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study.

Giacomo De Luca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.